Fecha de inicio

2020

Fecha de finalización

2025

Coordinador

Felipe Prósper

Funding agency

European Commission BRAV∃


Ischemic heart disease (coronary artery disease) is the leading single cause of death in Europe. Biomedical researchers are seeking solutions in self-repairing mechanisms of tissues or organs. However, the most promising solution lies in advancements in cell reprogramming, biomaterials or 3D printing combined with the profound study of myocardial physiology. The EU-funded BRAV3 project will develop a lasting biological device able to pump alongside a damaged heart through the engineering of a regenerative tissue with the use of biomaterials, stem cells and advanced computational modelling with 3D printable designs. By developing biological ventricular assist devices (BioVADs), BRAV3 will bring a quantum leap in regenerative medicine and its translation towards the clinic, as well as impact the development of novel medical technologies whilst greatly advancing our knowledge on human heart development.